Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer

Nature·Jul 11

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research is being conducted on the biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer. Studies are investigating various aspects, including resistance to these treatments, potential therapeutic opportunities, and cost-effectiveness. The findings may provide insights into the effectiveness of these treatments and potential biomarkers for breast cancer.

Full coverage

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

Nature·Mar 26

LEM4 interacts with β-catenin and promotes β-catenin-dependent transcription activity to confers ribociclib resistance in breast cancer cells

Nature·Dec 24

CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction

Nature·Jan 22

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities

Nature·Aug 5

Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines

Nature·Jul 31

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy | npj Breast Cancer

Nature·Mar 6

Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Nature·Apr 14

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

Nature·Aug 16

View original report at Nature ↗

Fetching the latest headlines…